Core Viewpoint - Investors in uniQure N.V. have the opportunity to lead a securities fraud lawsuit against the company due to alleged violations of the Securities Exchange Act of 1934, specifically related to misleading statements about FDA approval and BLA timelines [1] Group 1: Lawsuit Details - The Schall Law Firm is reminding investors of a class action lawsuit against uniQure N.V. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is defined as between September 24, 2025, and October 31, 2025, during which investors are encouraged to contact the firm before April 13, 2026 [1] - The lawsuit claims that uniQure made false and misleading statements regarding its ability to secure full FDA approval for its Pivotal Study and misrepresented the likelihood of delaying its BLA timeline [1] Group 2: Investor Impact - Investors who purchased uniQure's securities during the class period reportedly suffered damages when the truth about the company's misleading statements was revealed [1] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally, indicating a focus on protecting shareholder rights [1]

Group 1 - Rosen Law Firm has announced a class action lawsuit on behalf of shareholders of BlackRock TCP Capital Corp. (NASDAQ: TCPC) for the period between November 6, 2024, and January 23, 2026 [1] - The lawsuit alleges that BlackRock TCP misled investors regarding its business operations, including failing to disclose that investments were not being timely or appropriately valued [1] - The firm claims that BlackRock TCP's unrealized losses were understated and its net asset value (NAV) was overstated, leading to materially misleading statements about the company's prospects [1] Group 2 - Shareholders wishing to serve as lead plaintiffs must file motions with the court by April 6, 2026, and they do not need to participate in the case to be eligible for recovery [1] - Rosen Law Firm operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless they recover losses [1] - The firm has a history of obtaining over $1 billion for shareholders and is recognized for its commitment to shareholder rights litigation [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged material misstatements regarding its drug setrusumab, with a deadline for investors to seek lead plaintiff status set for April 6, 2026 [1] Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1] - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed risks associated with its Phase III Orbit study [1] - Defendants are accused of making misleading statements about the company's business and prospects, lacking a reasonable basis for their optimism [1] Group 2: Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing for lead plaintiff status by the April 6, 2026 deadline [1] - Options for investors include retaining counsel or taking no action, with the ability to remain an absent class member [1] - The lead plaintiff will represent all class members and is typically the investor with the largest financial interest [1]

Core Viewpoint - Paysafe Limited (PSFE) is facing a class action lawsuit due to alleged securities fraud, following a significant drop in its stock price after disappointing financial results were announced [1] Financial Performance - For Q3 2025, Paysafe reported revenue of $433.8 million, missing consensus estimates by $5.8 million - The company experienced a net loss of $87.7 million, a substantial increase from a net loss of $12.98 million in the same period the previous year - Full year 2025 expected revenue was revised down to $17 million at the midpoint, with adjusted EPS projected at $0.50 [1] Issues Leading to Lawsuit - The lawsuit alleges that Paysafe's ecommerce business had significant exposure to a single high-risk client, leading to understated credit loss reserves and write-offs - The company faced undisclosed issues with higher risk Merchant Category Codes, complicating its banking relationships - These factors were likely to negatively impact revenue growth and overall revenue mix, making it unlikely for Paysafe to meet its previously issued financial guidance for fiscal year 2025 [1] Stock Market Reaction - Following the announcement of the financial results, Paysafe's stock price fell by $2.80, or 27.6%, closing at $7.36 per share on November 13, 2025, with unusually high trading volume [1]

Core Viewpoint - Kyndryl Holdings, Inc. is under investigation for potential securities fraud following a significant stock drop of over 52% due to an accounting review and the departure of key executives [1][1][1] Group 1: Investigation Details - The investigation is being conducted by Bleichmar Fonti & Auld LLP to determine if Kyndryl misrepresented its cash management practices and the drivers of its adjusted free cash flow metric [1][1] - The inquiry focuses on Kyndryl's internal controls over financial reporting for FY2025 and the first three quarters of FY2026 [1][1] Group 2: Stock Performance - Kyndryl's stock price fell by more than 52% on February 9, 2026, following the announcement of a delay in the release of its fiscal Q3 2026 financial statement due to an accounting review [1][1] - The stock drop was exacerbated by the immediate departures of the CFO and General Counsel [1][1]

Core Viewpoint - Ademi LLP is investigating potential securities fraud claims against Stellantis N.V. due to possibly inaccurate statements regarding its business operations and future prospects [1] Group 1: Investigation Focus - The investigation centers on whether Stellantis has been experiencing "poor operational execution" in its strategy to boost sales of electric vehicles [1] - Concerns are raised about the quality control of Stellantis' manufacturing processes [1] Group 2: Legal Context - Ademi LLP specializes in securities fraud and shareholder litigation, indicating a focus on protecting shareholder interests [1] - The investigation is being conducted without any cost or obligation to participants [1]

Core Viewpoint - Ramaco Resources, Inc. is facing a class action lawsuit due to allegations of securities fraud related to misleading statements about its Brook Mine operations, which were claimed to be non-existent or exaggerated during the specified class period [1]. Group 1: Lawsuit Details - The class action lawsuit is filed on behalf of investors who purchased Ramaco securities between July 31, 2025, and October 23, 2025 [1]. - The lawsuit alleges that Ramaco made materially false and misleading statements regarding the commencement and progress of mining activities at the Brook Mine [1]. - The report from Wolfpack Research claims that no significant mining activity occurred at the Brook Mine after its groundbreaking, leading to a significant drop in Ramaco's stock price by $3.81, or 9.6%, to close at $36.01 per share on October 23, 2025 [1]. Group 2: Allegations Against the Company - The lawsuit claims that Ramaco failed to disclose that no active work was taking place at the Brook Mine, which misled investors about the company's operational status [1]. - It is alleged that the company overstated development progress at the Brook Mine, which contributed to the misleading nature of its positive statements about business prospects [1]. - The lawsuit emphasizes that the defendants' statements lacked a reasonable basis, further compounding the misleading information provided to investors [1].

Core Viewpoint - Robbins LLP has announced a class action lawsuit against Picard Medical, Inc. for alleged fraudulent stock promotion activities that misled investors [1] Group 1: Allegations Against Picard Medical, Inc. - The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [1] - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [1] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] Group 2: Stock Price Impact - On October 24, 2025, Picard Medical's stock price fell sharply by 70%, dropping to $3.99 per share [1] - Following the initial crash, the stock price has continued to decline, reaching approximately $2.00 per share [1] Group 3: Class Action Participation - Investors who purchased Picard Medical securities between September 2, 2025, and October 31, 2025, may be eligible to participate in the class action [1] - Shareholders wishing to serve as lead plaintiff must file their papers with the court by April 3, 2026 [1] - Participation in the case is not required to be eligible for recovery, allowing investors to remain absent class members if they choose [1]

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of SkyWater Technology, Inc. to IonQ, focusing on the adequacy of the price and the process leading to the transaction [1] Group 1: Proposed Transaction Details - Under the terms of the proposed sale, shareholders of SkyWater will receive $15.00 in cash and $20.00 in shares of IonQ common stock for each share of SkyWater owned [1] - The investigation aims to determine if the consideration offered undervalues SkyWater Technology [1] Group 2: Legal Inquiry - Kahn Swick & Foti, LLC is seeking to assess the adequacy of the proposed transaction and the process that led to it [1] - Shareholders who believe the transaction undervalues the company are encouraged to discuss their legal rights with KSF [1]

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of Stellar Bancorp, Inc. to Prosperity Bancshares, Inc. for 0.3803 shares of Prosperity common stock and $11.36 in cash per share of Stellar common stock, focusing on whether the transaction is fair to Stellar shareholders [1]. Group 1: Investigation Details - The investigation aims to determine if Stellar Bancorp and its board violated federal securities laws or breached fiduciary duties by not securing the best possible consideration for shareholders [1]. - Key concerns include whether Prosperity is underpaying for Stellar and if all material information necessary for shareholders to assess the merger consideration has been disclosed [1]. Group 2: Legal Representation - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [1]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [1].